Thoracic oncology conducts cutting-edge diagnostic and therapeutic research related to lung cancer and malignant mesothelioma.
Faculty members in Penn Medicine's pulmonary division, led by Steven Albelda, MD, interact closely with faculty from thoracic surgery, oncology and pathology to conduct cutting-edge diagnostic and therapeutic investigations related to lung cancer and malignant mesothelioma.
Research from this group is supported by an NCI-funded program project, and a grant from the Pennsylvania Department of Health and Foundation.
Members of the group and their research interests include:
- Preclinical studies of immunogene therapy for lung cancer and mesothelioma
- Immune analysis of clinical trials using gene therapy or immunotherapy
- Mesothelioma and cancer genomics
- Personalized medicine
Melpo Christofidou-Solomidou, PhD
- Chemoprevention of lung carcinogenesis and evaluation of anti-carcinogenic effects of common botanicals
- Clinical trials using gene therapy or immunotherapy to treat malignant mesothelioma and lung cancer
- Interventional bronchoscopy treatment of COPD
- Determination of markers to predict survival after lung cancer surgery
- Discovery of biomarkers for early detection of lung cancer
- Gene environment interactions in lung cancer
- Combining surgery with immunotherapy